Pliant Therapeutics Inc (PLRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) has a cash flow conversion efficiency ratio of -0.105x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.08 Million) by net assets ($200.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pliant Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Pliant Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PLRX current and long-term liabilities for a breakdown of total debt and financial obligations.
Pliant Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pliant Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Flag Ship Acquisition Corp. Unit
NASDAQ:FSHPU
|
-0.006x |
|
Pylon Public Company Limited
BK:PYLON
|
0.075x |
|
Gemvaxlink Co. Ltd
KQ:064800
|
-0.021x |
|
Inoue Rubber (Thailand) Public Company Limited
BK:IRC
|
0.034x |
|
Coeptis Therapeutics Inc
NASDAQ:COEP
|
-0.165x |
|
Engenco Ltd
AU:EGN
|
0.101x |
|
Epitomee Medical Ltd
TA:EPIT
|
-0.416x |
|
Brimag -L
TA:BRMG
|
0.106x |
Annual Cash Flow Conversion Efficiency for Pliant Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Pliant Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Pliant Therapeutics Inc (PLRX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $304.08 Million | $-155.50 Million | -0.511x | -108.13% |
| 2023-12-31 | $473.58 Million | $-116.36 Million | -0.246x | +18.64% |
| 2022-12-31 | $313.34 Million | $-94.63 Million | -0.302x | +20.31% |
| 2021-12-31 | $199.06 Million | $-75.44 Million | -0.379x | -187.84% |
| 2020-12-31 | $283.06 Million | $-37.27 Million | -0.132x | -102.08% |
| 2019-12-31 | $-435.00K | $-2.75 Million | 6.322x | -80.32% |
| 2018-12-31 | $-882.00K | $-28.33 Million | 32.118x | +738.60% |
| 2017-12-31 | $3.37 Million | $-16.92 Million | -5.029x | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral,… Read more